3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
4
Phase 2
3
Phase 3
2
Phase 1
1
Status
Withdrawn
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
14
Recurrence
2
Neoplasms, Plasma Cell
1
Lymphoma
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
elotuzumab
×
Clear all
NCT06232707
2024-05-31
ALUMMINATE
Celgene
Phase 3
Withdrawn
NCT03651128
2022-12-15
KarMMa-3
Celgene
Phase 3
Active not recruiting
381 enrolled